{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:02:39Z","timestamp":1791068559696,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,2,25]],"date-time":"2012-02-25T00:00:00Z","timestamp":1330128000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11926-012-0246-6","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T16:02:04Z","timestamp":1330099324000},"page":"264-274","source":"Crossref","is-referenced-by-count":148,"title":["Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment"],"prefix":"10.1007","volume":"14","author":[{"given":"Tsuneyo","family":"Mimori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,25]]},"reference":[{"key":"246_CR1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/ijr.10.48","volume":"5","author":"R Nakashima","year":"2010","unstructured":"Nakashima R, Mimori T. Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies. Int J Clin Rheumatol. 2010;5:523\u201336.","journal-title":"Int J Clin Rheumatol"},{"key":"246_CR2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/157339710791330740","volume":"6","author":"LA Saketkoo","year":"2010","unstructured":"\u2022 Saketkoo LA, Ascherman DP, Cottin V, et al. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev. 2010;6:108\u201319. This is a good review of ILD in IIM focusing on the pathogenesis, clinical manifestation, diagnosis and disease monitoring, and therapeutics.","journal-title":"Curr Rheumatol Rev"},{"key":"246_CR3","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"\u2022 Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies. What progress has been made in the past 35 years? Chest. 2010;138:1464\u201374. This is a good review of ILD in IIM focusing on pathogenesis, diagnosis, and current therapeutic approaches.","journal-title":"Chest"},{"key":"246_CR4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/BOR.0b013e32833f1970","volume":"22","author":"A Labirua","year":"2010","unstructured":"\u2022 Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol. 2010;22:633\u20138. This is a good review describing recent findings regarding ILD in IIM, focusing on the phenotypes of ILD, autoantibodies, pathogenesis, and treatment.","journal-title":"Curr Opin Rheumatol."},{"key":"246_CR5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1378\/chest.65.4.403","volume":"65","author":"AR Frazier","year":"1974","unstructured":"Frazier AR, Miller RD. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest. 1974;65:403\u20137.","journal-title":"Chest"},{"key":"246_CR6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","volume":"47","author":"I Marie","year":"2002","unstructured":"Marie I, Hachulla E, Ch\u00e9rin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614\u201322.","journal-title":"Arthritis Rheum"},{"key":"246_CR7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/sarh.2002.50012","volume":"32","author":"A Schnabel","year":"2003","unstructured":"Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32:273\u201384.","journal-title":"Semin Arthritis Rheum"},{"key":"246_CR8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/ard.2003.006122","volume":"63","author":"M Fathi","year":"2004","unstructured":"Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297\u2013301.","journal-title":"Ann Rheum Dis"},{"key":"246_CR9","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/rheumatology\/keh723","volume":"44","author":"EH Kang","year":"2005","unstructured":"Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44:1282\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR10","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","volume":"26","author":"S Ye","year":"2007","unstructured":"Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26:1647\u201354.","journal-title":"Clin Rheumatol"},{"key":"246_CR11","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.rmed.2007.02.017","volume":"101","author":"J Won Huh","year":"2007","unstructured":"Won Huh J, Soon Kim D, Keun Lee C, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med. 2007;101:1761\u20139.","journal-title":"Respir Med"},{"key":"246_CR12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.23571","volume":"59","author":"M Fathi","year":"2008","unstructured":"Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59:677\u201385.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"246_CR13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10067-009-1110-6","volume":"28","author":"IJ Chen","year":"2009","unstructured":"Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009;28(6):639\u201346.","journal-title":"Clin Rheumatol."},{"key":"246_CR14","first-page":"58","volume":"32","author":"T Fujisawa","year":"2005","unstructured":"Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005;32:58\u201364.","journal-title":"J Rheumatol"},{"key":"246_CR15","first-page":"260","volume":"35","author":"S Hayashi","year":"2008","unstructured":"Hayashi S, Tanaka M, Kobayashi H, et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis\/dermatomyositis. J Rheumatol. 2008;35:260\u20139.","journal-title":"J Rheumatol"},{"key":"246_CR16","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3899\/jrheum.101002","volume":"38","author":"Y Yamasaki","year":"2011","unstructured":"\u2022 Yamasaki Y, Yamada H, Ohkubo M, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636\u201343. Erratum in: J Rheumatol 2011, 38:1815\u20131816. This retrospective study analyzed the long-term survival and associated risk factors of 197 IIM patients and suggested that ILD is the main cause of death in DM and C-ADM.","journal-title":"J Rheumatol"},{"key":"246_CR17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/art.1780230802","volume":"23","author":"M Nishikai","year":"1980","unstructured":"Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: characterization of the Jo-1 antibody system. Arthritis Rheum. 1980;23:881\u20138.","journal-title":"Arthritis Rheum"},{"key":"246_CR18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/304177a0","volume":"304","author":"MB Mathews","year":"1983","unstructured":"Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature. 1983;304:177\u20139.","journal-title":"Nature"},{"key":"246_CR19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1084\/jem.160.2.420","volume":"160","author":"MB Mathews","year":"1984","unstructured":"Mathews MB, Reichlin M, Hughes GRV, et al. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med. 1984;160:420\u201334.","journal-title":"J Exp Med"},{"key":"246_CR20","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.163.5.1281","volume":"163","author":"CC Bunn","year":"1986","unstructured":"Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAala coexist and are associated with myositis. J Exp Med. 1986;163:1281\u201391.","journal-title":"J Exp Med"},{"key":"246_CR21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/art.1780350718","volume":"35","author":"IN Targoff","year":"1992","unstructured":"Targoff IN, Trieu EP, Plotz PH, et al. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 1992;35:821\u201330.","journal-title":"Arthritis Rheum"},{"key":"246_CR22","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1172\/JCI116493","volume":"91","author":"IN Targoff","year":"1993","unstructured":"Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993;91:2556\u201364.","journal-title":"J Clin Invest"},{"key":"246_CR23","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4049\/jimmunol.162.4.2315","volume":"162","author":"M Hirakata","year":"1999","unstructured":"Hirakata M, Suwa A, Nagai S, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol. 1999;162:2315\u201320.","journal-title":"J Immunol"},{"key":"246_CR24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kem045","volume":"46","author":"Z Betteridge","year":"2007","unstructured":"Betteridge Z, Gunawardena H, North J, et al. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford). 2007;46:1005\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR25","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1002\/art.20784","volume":"52","author":"L Hashish","year":"2005","unstructured":"Hashish L, Trieu EP, Sadanandan P, et al. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with anti-synthetase syndrome (abstract). Arthritis Rheum. 2005;52:S312.","journal-title":"Arthritis Rheum"},{"key":"246_CR26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0889-857X(21)00070-3","volume":"20","author":"IN Targoff","year":"1994","unstructured":"Targoff IN. Immune manifestation of inflammatory muscle disease. Rheum Dis Clin North Am. 1994;20:857\u201380.","journal-title":"Rheum Dis Clin North Am"},{"key":"246_CR27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.1780260505","volume":"26","author":"S Yoshida","year":"1983","unstructured":"Yoshida S, Akizuki M, Mimori T, et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983;26:604\u201311.","journal-title":"Arthritis Rheum"},{"key":"246_CR28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","volume":"77","author":"C Marguerie","year":"1990","unstructured":"Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77:1019\u201338.","journal-title":"Q J Med"},{"key":"246_CR29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/08916930600622884","volume":"39","author":"H Yoshifuji","year":"2006","unstructured":"Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39:233\u201341.","journal-title":"Autoimmunity"},{"key":"246_CR30","first-page":"1012","volume":"34","author":"T Matsushita","year":"2007","unstructured":"Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007;34:1012\u20138.","journal-title":"J Rheumatol"},{"key":"246_CR31","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/art.24631","volume":"60","author":"TJ Richards","year":"2009","unstructured":"\u2022 Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60:2183\u201392. Ninety patients with anti-Jo-1 antibody were analyzed, and 86% of the cases were associated with ILD. A significant association between anti-Jo-1-positive ILD and elevated levels of interferon-\u03b3-inducible chemokines CXCL9 and CXCL10 was revealed.","journal-title":"Arthritis Rheum"},{"key":"246_CR32","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/art.22506","volume":"56","author":"M Hirakata","year":"2007","unstructured":"Hirakata M, Suwa A, Takada T, et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum. 2007;56:1295\u2013303.","journal-title":"Arthritis Rheum"},{"key":"246_CR33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel435","volume":"46","author":"S Sato","year":"2007","unstructured":"Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford). 2007;46:842\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR34","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1378\/chest.08-2233","volume":"135","author":"M Kalluri","year":"2009","unstructured":"\u2022 Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009;135:1550\u20136. A total of 31 patients with anti-PL-12 antibody were analyzed, and anti-PL-12 was strongly associated with the presence of ILD, but less so with myositis and arthritis.","journal-title":"Chest"},{"key":"246_CR35","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.rmed.2009.05.001","volume":"103","author":"A Fischer","year":"2009","unstructured":"Fischer A, Swigris JJ, du Bois RM, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103:1719\u201324.","journal-title":"Respir Med"},{"key":"246_CR36","first-page":"609","volume":"23","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, et al. Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol. 2005;23:609\u201315.","journal-title":"Clin Exp Rheumatol"},{"key":"246_CR37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2169\/internalmedicine.49.2889","volume":"49","author":"Y Koreeda","year":"2010","unstructured":"\u2022 Koreeda Y, Higashimoto I, Yamamoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med. 2010;49:361\u20139. Clinicopathological characteristics of ILD in 14 patients with antisynthetase syndrome were reviewed. Chronic clinical course, lung-base GGO with volume loss, NSIP pattern, and good response to corticosteroids were the characteristic features.","journal-title":"Intern Med"},{"key":"246_CR38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2249.1997.4081308.x","volume":"109","author":"SA Rutjes","year":"1997","unstructured":"Rutjes SA, Vree Egberts WT, Jongen P, et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 1997;109:32\u201340.","journal-title":"Clin Exp Immunol"},{"key":"246_CR39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","volume":"39","author":"R Corte La","year":"2006","unstructured":"La Corte R, Lo Mo Naco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39:249\u201353.","journal-title":"Autoimmunity"},{"key":"246_CR40","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","volume":"29","author":"A Vancsa","year":"2009","unstructured":"Vancsa A, Csipo I, Nemeth J, et al. Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients. Rheumatol Int. 2009;29:989\u201394.","journal-title":"Rheumatol Int"},{"key":"246_CR41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaut.2007.07.005","volume":"29","author":"Y Katsumata","year":"2007","unstructured":"Katsumata Y, Ridgway WM, Oriss T, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007;29:174\u201386.","journal-title":"J Autoimmun."},{"key":"246_CR42","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/art.24683","volume":"60","author":"S Barbasso Helmers","year":"2009","unstructured":"\u2022 Barbasso Helmers S, Englund P, Engstr\u00f6m M, et al. Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum. 2009;60:2524\u201330. Erratum in: Arthritis Rheum 2009, 60:2746. Sera from PM-ILD with anti-Jo-1 antibody (but perhaps not with the antibody itself) showed a strong effect on the expression of ICAM-1 from endothelial cells from human lung.","journal-title":"Arthritis Rheum"},{"key":"246_CR43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20020186","volume":"196","author":"OM Howard","year":"2002","unstructured":"Howard OM, Dong HF, Yang D, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196:781\u201391.","journal-title":"J Exp Med"},{"key":"246_CR44","doi-asserted-by":"crossref","first-page":"124S","DOI":"10.1038\/jid.1993.35","volume":"100","author":"RL Euwer","year":"1993","unstructured":"Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993;100:124S\u20137S.","journal-title":"J Invest Dermatol"},{"key":"246_CR45","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626\u201336.","journal-title":"J Am Acad Dermatol"},{"key":"246_CR46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1183\/09031936.03.00026703","volume":"22","author":"V Cottin","year":"2003","unstructured":"Cottin V, Thivolet-B\u00e9jui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003;22:245\u201350.","journal-title":"Eur Respir J"},{"key":"246_CR47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/0885066605275391","volume":"20","author":"T Yokoyama","year":"2005","unstructured":"Yokoyama T, Sakamoto T, Shida N, et al. Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes. J Intensive Care Med. 2005;20:160\u20133.","journal-title":"J Intensive Care Med"},{"key":"246_CR48","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1183\/09031936.06.00038806","volume":"28","author":"T Suda","year":"2006","unstructured":"Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28:1005\u201312.","journal-title":"Eur Respir J"},{"key":"246_CR49","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","volume":"54","author":"P Gerami","year":"2006","unstructured":"Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597\u2013613.","journal-title":"J Am Acad Dermatol"},{"key":"246_CR50","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1378\/chest.08-2740","volume":"136","author":"H Mukae","year":"2009","unstructured":"Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136:1341\u20137.","journal-title":"Chest"},{"key":"246_CR51","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571\u20136.","journal-title":"Arthritis Rheum"},{"key":"246_CR52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","volume":"49","author":"R Nakashima","year":"2010","unstructured":"\u2022\u2022 Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49:433\u201340. In this article, the target autoantigen recognized by anti-CADM-140 antibody was identified as IFIH1\/MDA5, and at first the association between anti-CADM-140-positive patients and hyperferritinemia was described.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR53","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","volume":"49","author":"K Hoshino","year":"2010","unstructured":"\u2022 Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49:1726\u201333. Anti-CADM-140 (MDA5) and anti-TIF1-\u03b3 antibodies were detected by a new method immunoprecipitating with biotinylated recombinant MDA5 and TIF1-\u03b3. A total of 26% and 65% were positive for anti-MDA5 in DM and C-ADM, respectively; 95% of the antibody-positive patients had ILD.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"246_CR54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2474-11-223","volume":"11","author":"EH Kang","year":"2010","unstructured":"Kang EH, Nakashima R, Mimori T, et al. Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010;11(1):223.","journal-title":"BMC Musculoskelet Disord."},{"key":"246_CR55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25\u201334.","journal-title":"J Am Acad Dermatol"},{"key":"246_CR56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","volume":"147","author":"Y Hamaguchi","year":"2011","unstructured":"Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391\u20138.","journal-title":"Arch Dermatol"},{"key":"246_CR57","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","volume":"49","author":"T Gono","year":"2010","unstructured":"\u2022\u2022 Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713\u20139. In this article, serum ferritin level was reported to be significantly high in the subset with anti-CADM-140 (MDA5) antibody, which correlates with disease activity and predicts prognosis.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR58","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/keq196","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono T, Kawaguchi Y, Sugiura T, et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford). 2010;49:1878\u201381.","journal-title":"Rheumatology (Oxford)."},{"key":"246_CR59","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"\u2022\u2022 Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193\u2013200. This is an important article that first identified the target autoantigen recognized by anti-CADM-140 antibody to be MDA5.","journal-title":"Arthritis Rheum"},{"key":"246_CR60","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/art.1780291109","volume":"29","author":"ML Christensen","year":"1986","unstructured":"Christensen ML, Pachman LM, Schneiderman R, et al. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 1986;29:1365\u201370.","journal-title":"Arthritis Rheum"},{"key":"246_CR61","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(87)92271-9","volume":"1","author":"NE Bowles","year":"1987","unstructured":"Bowles NE, Dubowitz V, Sewry CA, et al. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet. 1987;1:1004\u20137.","journal-title":"Lancet"},{"key":"246_CR62","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/rheumatology\/39.9.1037","volume":"39","author":"G Chevrel","year":"2000","unstructured":"Chevrel G, Calvet A, Belin V, et al. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford). 2000;39:1037\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR63","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","volume":"164","author":"WW Douglas","year":"2001","unstructured":"Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"246_CR64","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccm.2010.05.008","volume":"31","author":"M Kalluri","year":"2010","unstructured":"Kalluri M, Oddis CV. Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med. 2010;31:501\u201312.","journal-title":"Clin Chest Med"},{"key":"246_CR65","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2169\/internalmedicine.48.1714","volume":"48","author":"T Daimon","year":"2009","unstructured":"Daimon T, Johkoh T, Honda O, et al. Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types. Intern Med. 2009;48:753\u201361.","journal-title":"Intern Med"},{"key":"246_CR66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2214\/ajr.169.1.9207505","volume":"169","author":"M Mino","year":"1997","unstructured":"Mino M, Noma S, Taguchi Y, et al. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol. 1997;169:83\u20137.","journal-title":"AJR Am J Roentgenol"},{"key":"246_CR67","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.rmed.2011.03.022","volume":"105","author":"K Watanabe","year":"2011","unstructured":"\u2022 Watanabe K, Handa T, Tanizawa K, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011;105:1238\u201347. Antisynthetase antibodies were detected in 13 patients (6.6%) from 198 with idiopathic interstitial pneumonia. On HRCT, GGO and traction bronchiectasis were the major findings in these patients.","journal-title":"Respir Med"},{"key":"246_CR68","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","volume":"105","author":"K Tanizawa","year":"2011","unstructured":"\u2022\u2022 Tanizawa K, Handa T, Nakashima R, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Resp Med. 2011;105:1380\u20137. HRCT pattern of anti-CADM-140-positive ILD was described. Lower consolidation or GGO pattern and random GGO pattern, but the absence of intralobular reticular opacities, were the characteristic HRCT findings in these patients.","journal-title":"Resp Med"},{"key":"246_CR69","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.59.4.257","volume":"59","author":"S Bandoh","year":"2000","unstructured":"Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis\/dermatomyositis. Ann Rheum Dis. 2000;59:257\u201362.","journal-title":"Ann Rheum Dis"},{"key":"246_CR70","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/rheumatology\/39.6.632","volume":"39","author":"M Kubo","year":"2000","unstructured":"Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000;39:632\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR71","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","volume":"165","author":"H Ohnishi","year":"2002","unstructured":"Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"246_CR72","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2796.2006.01704.x","volume":"260","author":"H Satoh","year":"2006","unstructured":"Satoh H, Kurishima K, Ishikawa H, et al. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006;260:429\u201334.","journal-title":"J Intern Med"},{"key":"246_CR73","first-page":"414","volume":"26","author":"G Kum\u00e1novics","year":"2008","unstructured":"Kum\u00e1novics G, Minier T, Radics J, P\u00e1link\u00e1s L, et al. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato\/polymyositis. Clin Exp Rheumatol. 2008;26:414\u201320.","journal-title":"Clin Exp Rheumatol"},{"key":"246_CR74","doi-asserted-by":"crossref","unstructured":"Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2011;Sep 23. [Epub ahead of print].","DOI":"10.1111\/j.1365-2796.2011.02459.x"},{"key":"246_CR75","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","volume":"49","author":"T Gono","year":"2010","unstructured":"\u2022 Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1354\u201360. Significantly high levels of serum ferritin were observed in DM patients with acute or subacute ILD, and patients with ferritin levels higher than 1,500 ng\/mL showed poor prognosis.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR76","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10165-010-0371-x","volume":"21","author":"T Gono","year":"2011","unstructured":"Gono T, Kawaguchi Y, Ozeki E, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 2011;21:223\u20137.","journal-title":"Mod Rheumatol"},{"key":"246_CR77","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","volume":"56","author":"KB Stone","year":"2007","unstructured":"Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56:3125\u201331.","journal-title":"Arthritis Rheum"},{"key":"246_CR78","doi-asserted-by":"crossref","unstructured":"Sato S, Kuwana M, Fujita T, et al. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140\/MDA5 autoantibodies. Mod Rheumatol. 2011;Nov 29. [Epub ahead of print].","DOI":"10.1007\/s10165-011-0558-9"},{"key":"246_CR79","first-page":"1527","volume":"26","author":"Y Nawata","year":"1999","unstructured":"Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis\/polymyositis: prediction and treatment with cyclosporine. J Rheumatol. 1999;26:1527\u201333.","journal-title":"J Rheumatol"},{"key":"246_CR80","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2169\/internalmedicine.36.519","volume":"36","author":"T Shinohara","year":"1997","unstructured":"Shinohara T, Hidaka T, Matsuki Y, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med. 1997;36:519\u201323.","journal-title":"Intern Med"},{"key":"246_CR81","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2169\/internalmedicine.38.733","volume":"38","author":"T Yoshida","year":"1999","unstructured":"Yoshida T, Koga H, Saitoh F, et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med. 1999;38:733\u20138.","journal-title":"Intern Med"},{"key":"246_CR82","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","volume":"46","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis. Rheumatology (Oxford). 2007;46:124\u201330.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR83","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2169\/internalmedicine.39.428","volume":"39","author":"F Tanaka","year":"2000","unstructured":"Tanaka F, Origuchi T, Migita K, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med. 2000;39:428\u201330.","journal-title":"Intern Med"},{"key":"246_CR84","first-page":"1719","volume":"32","author":"H Kameda","year":"2005","unstructured":"Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719\u201326.","journal-title":"J Rheumatol"},{"key":"246_CR85","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/03009749709065660","volume":"26","author":"K Maeda","year":"1997","unstructured":"Maeda K, Kimura R, Komuta K, et al. Cyclosporine treatment for polymyositis\/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol. 1997;26:24\u20139.","journal-title":"Scand J Rheumatol"},{"key":"246_CR86","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/08916930500124023","volume":"38","author":"K Takada","year":"2005","unstructured":"Takada K, Nagasaka K, Miyasaka N. Polymyositis\/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38:383\u201392.","journal-title":"Autoimmunity"},{"key":"246_CR87","first-page":"254","volume":"35","author":"T Kotani","year":"2008","unstructured":"Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute\/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2008;35:254\u20139.","journal-title":"J Rheumatol"},{"key":"246_CR88","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-011-1713-6","volume":"30","author":"T Kotani","year":"2011","unstructured":"\u2022 Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute\/subacute interstitial pneumonia. Clin Rheumatol. 2011;30:1021\u20138. The efficacy of a combination with corticosteroids and CSP was reported in 14 DM patients with acute or subacute ILD.","journal-title":"Clin Rheumatol"},{"key":"246_CR89","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10165-010-0342-2","volume":"21","author":"K Nagai","year":"2011","unstructured":"\u2022 Nagai K, Takeuchi T, Kotani T, et al. Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis. Mod Rheumatol. 2011;21:32\u20136. CSP blood level, especially C0 and C2, is useful to monitor clinical and adverse effects of CSP, and once-daily preprandial administration is beneficial in DM patients with progressive ILD.","journal-title":"Mod Rheumatol"},{"key":"246_CR90","first-page":"707","volume":"23","author":"S Ochi","year":"2005","unstructured":"Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis\/dermatomyositis. Clin Exp Rheumatol. 2005;23:707\u201310.","journal-title":"Clin Exp Rheumatol"},{"key":"246_CR91","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","volume":"353","author":"CV Oddis","year":"1999","unstructured":"Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762\u20133.","journal-title":"Lancet"},{"key":"246_CR92","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","volume":"52","author":"MR Wilkes","year":"2005","unstructured":"Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439\u201346.","journal-title":"Arthritis Rheum"},{"key":"246_CR93","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","volume":"48","author":"M Sem","year":"2009","unstructured":"\u2022 Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48:968\u201371. Eleven refractory ILD patients with antisynthetase syndrome were treated with rituximab, and 7 of 11 showed a short-term beneficial effect on ILD.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR94","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00296-009-0859-x","volume":"29","author":"E Vandenbroucke","year":"2009","unstructured":"Vandenbroucke E, Grutters JC, Altenburg J, et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int. 2009;29:1499\u2013502.","journal-title":"Rheumatol Int"},{"key":"246_CR95","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/rheumatology\/kep438","volume":"49","author":"EM Ball","year":"2010","unstructured":"Ball EM, Savage EM, Pendleton A. Refractory anti-synthetase syndrome treated with rituximab. Rheumatology (Oxford). 2010;49:1013.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR96","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","volume":"337","author":"LA Saketkoo","year":"2009","unstructured":"\u2022 Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337:329\u201335. MMF was administered to 10 patients with autoimmune-related ILD (including 2 PM), and all patients showed stabilization and\/or improvement of the disease.","journal-title":"Am J Med Sci"},{"key":"246_CR97","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/acr.20046","volume":"62","author":"PA Morganroth","year":"2010","unstructured":"\u2022 Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken). 2010;62:496\u2013501. Three of four patients with DM-ILD who received MMF experienced improvement in pulmonary function and dyspnea and reduction of corticosteroid doses.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"246_CR98","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","volume":"187","author":"Y Suzuki","year":"2009","unstructured":"Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis. Lung. 2009;187:201\u20136.","journal-title":"Lung"},{"key":"246_CR99","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dasrmalchi","year":"2008","unstructured":"Dasrmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670\u20137.","journal-title":"Ann Rheum Dis"},{"key":"246_CR100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","volume":"70","author":"The Muscle Study Group","year":"2011","unstructured":"The Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427\u201336.","journal-title":"Ann Neurol"},{"key":"246_CR101","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","volume":"50","author":"M Narazaki","year":"2011","unstructured":"Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011;50:1344\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"246_CR102","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbspin.2007.07.010","volume":"75","author":"A Furlan","year":"2008","unstructured":"Furlan A, Botsios C, Ruffatti A, et al. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine. 2008;75:366\u20137.","journal-title":"Joint Bone Spine"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-012-0246-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-012-0246-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-012-0246-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T13:10:11Z","timestamp":1687266611000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-012-0246-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,25]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1007\/s11926-012-0246-6","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.14257969.15771074","asserted-by":"object"}]},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,25]]}}}